Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Annual Dosing Study of Donanemab in Participants Who Completed Study AACM
NCT07602582Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Primary completion
- Sep 2029
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of donanemab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started May 2026; status: recruiting.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07602582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07602582.